October 8, 2021

RE: Clarification #7 for Measurement Year (MY) 2021 Updates

Dear Colleague,

This letter contains information about edits incorporated into the 2020-2021 Quality Assurance Reporting Requirements (QARR) Technical Specifications for Measurement Year (MY) 2021 reporting.

The information contained in this clarification has been incorporated into a revised version of the MY2021 PLD specifications for the Exchange line of business.

The updated 2020-2021 PLD specification are posted on our Managed Care Information for Health Plans page. The revised specifications should be used in plans’ processing for MY2021 QARR.

Listed below are the changes and further explanation:

The following edits were made to the 2021 Patient-Level Detail (PLD) specifications:

**Products: Commercial PLD Specifications**
- For the retired Childhood Immunization Status combination rates 2,4,5,6,8,9, hard coding the numerators to “0” is acceptable if the plan is unable to report these results. [columns 91, 93, 94, 95, 97, 98]

**Products: Medicaid PLD Specifications**
- For the retired Childhood Immunization Status combination rates 2,4,5,6,8,9, hard coding the numerators to “0” is acceptable if the plan is unable to report these results. [columns 91, 93, 94, 95, 97, 98]

**Products: Exchange PLD Specifications**
- Childhood Immunization Status Combo 3 switched with Combo 10 [columns 88]
- Three (3) New columns added for Childhood Immunization Status [columns 89-91]
- Measures had column numbers changed to reflect the new measures added (+3 added to each subsequent column number) [columns 92-285]

For the changes made to the Exchange PLD Specifications regarding Childhood Immunization Status, NYS only requires antigens requested by CMS. The Exchange PLD
file has been updated to recognize CMS changes to QHP reporting that are referenced in the 2022 QRS Measure Technical Specifications and the Final 2021 Call Letter. This switches Childhood Immunization Status Combo 3 for Combo 10 at Column Start Point 88 and adds the three new required antigens of hepatitis A, rotavirus, and influenza at Column Start Points 89, 90, and 91, respectfully. With the swap at Column Start Point at 88 and the addition of three new antigens, this bumps out the rest of the PLD by +3 at each subsequent Column Start Point.

Also, please note for planning purposes we intend to require the Annual Dental Visit measure (ages 19-20) for the Essential Plan product line beginning in MY 2022.

If there are any questions about the above edits, or if you find issues or have concerns with the 2021 Technical Specifications manual or the 2021 PLD specifications, please email nysqarr@health.ny.gov.

Sincerely,

Paloma Luisi, MPH
Director
Bureau of Quality Measurement & Evaluation
Division Quality Measurement
Office of Quality and Patient Safety

CC: M.B. Conroy
M. Lurie